| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/19/2004 | WO2004014927A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | WO2004014849A2 Isosorbide mononitrate compositions and methods of their use |
| 02/19/2004 | WO2004014841A1 Compounds, pro-drugs and conjugates derived from mexiletine |
| 02/19/2004 | WO2004014432A1 Carrier |
| 02/19/2004 | WO2004014431A1 A parenteral dosage form of selective cox-2 inhibitors |
| 02/19/2004 | WO2004014424A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 02/19/2004 | WO2004014411A1 Nasal peptide pharmaceutical formulation |
| 02/19/2004 | WO2004014402A1 Activated carbon for preventing pregnancy and sexually transmitted disease |
| 02/19/2004 | WO2004014399A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 02/19/2004 | WO2004014397A1 Analgetic cream comprising salicylate dispersed in silicone oil and microsponges for substained delivery of counter-irritants like menthol |
| 02/19/2004 | WO2004014395A1 Female hormone-containing patch |
| 02/19/2004 | WO2004014390A1 Novel pharmaceutical composition of ceftiofur |
| 02/19/2004 | WO2004014373A1 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases |
| 02/19/2004 | WO2004014350A2 Polymer conjugates of a local anaesthetic drug |
| 02/19/2004 | WO2004014346A1 Palatable controlled-release formulation for companion animals |
| 02/19/2004 | WO2004014345A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 02/19/2004 | WO2004014344A1 Film coating for tablets and caplets |
| 02/19/2004 | WO2004014340A1 Injectable composition comprising florfenicol as an active ingredient |
| 02/19/2004 | WO2004014339A1 Injectable composition comprising ceftiofur sodium as an active ingredient |
| 02/19/2004 | WO2004014335A2 Dual-spike release formulation for oral drug delivery |
| 02/19/2004 | WO2004014322A2 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004014286A1 A capsule filling machine |
| 02/19/2004 | WO2004014156A2 A chemical carrier based on a beta-limit dextrin |
| 02/19/2004 | WO2004006886A3 Injectable depot formulation comprising crystals of iloperidone |
| 02/19/2004 | WO2004005326A3 Tubulysin conjugates |
| 02/19/2004 | WO2003105826A3 "soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors." |
| 02/19/2004 | WO2003103576A3 Reconstitutable compositions of biodegradable block copolymers |
| 02/19/2004 | WO2003092596A3 TREATING ECZEMA WITH A COMBINATION OF ISOTONIC SALINE OCEANè AND MAST CELL STABILIZERS |
| 02/19/2004 | WO2003059391A3 Viscoelastics for ocular surgery |
| 02/19/2004 | WO2003059251A3 Antibody targeting compounds |
| 02/19/2004 | WO2003053474A3 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 02/19/2004 | WO2003049593A3 Prevention of flap necrosis in plastic surgery |
| 02/19/2004 | WO2003047650A3 Preparation of red blood cells having reduced immunogenicity |
| 02/19/2004 | WO2003045411A3 Ginger extract preparation |
| 02/19/2004 | WO2003041744A3 Protease enzyme inhibitors |
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003020212A3 Treatment for central nervous system disorders |
| 02/19/2004 | WO2003000113A9 Compositions and methods for the diagnosis and treatment of tumor |
| 02/19/2004 | WO2002097072A8 Influenza vaccine composition |
| 02/19/2004 | WO2002091991A3 Substantially homogeneous bio-affecting material having a pre-determined ratio of bioaffecting component to cell targeting component, the method for making such a material and the method of its use |
| 02/19/2004 | WO2002091989A3 Antiviral therapies using polyamine or polyamine analog-amino acid conjugates |
| 02/19/2004 | WO2002065985A3 Methods of treating diabetes mellitus |
| 02/19/2004 | WO2002015887A8 Consumable container |
| 02/19/2004 | WO2001020981A3 Anti-infective compositions for treating disordered tissue such as cold sores |
| 02/19/2004 | US20040034338 Drug delivery devices and methods |
| 02/19/2004 | US20040034203 Polyol-modified silanes as precursors for silica |
| 02/19/2004 | US20040034108 Pharmaceutical formulation |
| 02/19/2004 | US20040034102 Oral pediatric trimethobenzamide formulations and methods |
| 02/19/2004 | US20040034068 New formulation and use thereof |
| 02/19/2004 | US20040034062 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 02/19/2004 | US20040034059 A dosage concentration about 0.4 to 75 mg/mL of fentanyl in water, for the pain treatment |
| 02/19/2004 | US20040034058 Inhalation asthma treatment with an aqueous solution of (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl)carbonyl)oxy) phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy)acetyl)amino) pentanoyl)amino) propanoic acid or a salt |
| 02/19/2004 | US20040034043 Positively-charged peptide nucleic acid analogs with improved properties |
| 02/19/2004 | US20040034042 Formulations containing a xanthine, e.g., caffeine, a buffer and a known preservative, e.g., sorbic acid, ethylenediamine-tetraacetic acid (EDTA) and salts; synergistic; storage stability; solutions and ointments of eyes; contact lenses |
| 02/19/2004 | US20040034021 Intravenous rifalazil formulation and methods of use thereof |
| 02/19/2004 | US20040033985 Composition for regulating animal growth, method of manufacture and use thereof |
| 02/19/2004 | US20040033982 Viral inhibition by n-docosanol |
| 02/19/2004 | US20040033957 FAP-activated anti-tumor prodrugs |
| 02/19/2004 | US20040033949 Use of VEGF for treating bone defects |
| 02/19/2004 | US20040033938 Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033584 Using immunoglobulins to diagnose and treat viral, fungal, bacterial and parasitic infections of the reticuloendothelial system; vetrinary medicine; immunotherapy |
| 02/19/2004 | US20040033556 Monascus purpureus mutant and its use in preparing yellow pigment |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033519 Binary or polynary targeting and uses thereof |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033345 Water soluble metal and semiconductor nanoparticle complexes |
| 02/19/2004 | US20040033275 Extracted with ethanol/water mixed with a heavy metal chelator; primary extract is concentrated with Indian Sterculia gum or one or more polymers such as a polysaccharides |
| 02/19/2004 | US20040033267 Nanoparticulate compositions of angiogenesis inhibitors |
| 02/19/2004 | US20040033263 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 02/19/2004 | US20040033262 Sustained release pharmaceutical composition of a cephalosporin antibiotic |
| 02/19/2004 | US20040033261 Gellan gum tablet film coating |
| 02/19/2004 | US20040033256 Long-acting insulin formulation that may be aerosolized for pulmonary administration. |
| 02/19/2004 | US20040033255 For preventing, inhibiting, and/or diminishing the intentional and/ or inadvertent misuse or abuse of a transdermal delivery device |
| 02/19/2004 | US20040033254 Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 02/19/2004 | US20040033247 Composition in the form of an emulsion that can be used to treat plantar bromhidrosis and/or hyperhidrosis |
| 02/19/2004 | US20040033245 Pharmaceutical suspensions, compositions and methods |
| 02/19/2004 | US20040033243 Containing stabilizer, solubilizer, chelator, bulking agent, tonicity adjuster and buffer; fewer degradants; consistent potency |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033211 Antigen arrays for treatment of bone disease |
| 02/19/2004 | US20040033210 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | US20040033201 Aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids |
| 02/19/2004 | US20040033195 Vitamin-targeted imaging agents |
| 02/19/2004 | DE10234784A1 Intravenös applizierbare, pharmazeutische Darreichungsform Administered Intravenously, pharmaceutical dosage form |
| 02/19/2004 | DE10217555A1 Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix Physiologically acceptable, phospholipid-containing, stable and hard matrix |
| 02/19/2004 | CA2495103A1 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases |
| 02/19/2004 | CA2495071A1 Isosorbide mononitrate compositions and methods of their use |
| 02/19/2004 | CA2494911A1 Immunomodulatory compositions, methods of making, and methods of use thereof |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494716A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 02/19/2004 | CA2494699A1 Palatable controlled-release formulation for companion animals |
| 02/19/2004 | CA2494677A1 Derivatives of monosaccharides for drug discovery |
| 02/19/2004 | CA2493019A1 Binding molecules |
| 02/19/2004 | CA2491136A1 A chemical carrier |
| 02/18/2004 | EP1389469A1 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 02/18/2004 | EP1389466A1 Immunopotentiators |
| 02/18/2004 | EP1389212A1 3,7-diazabicyclo 3.3.1] formulations as anti-arrythmic compounds |
| 02/18/2004 | EP1389211A1 3,7-diazybicyclo 3.3.1] formulations as antiarrhytmic compounds |